Ensuring Patient Access to Critical Breakthrough Products Act
Sponsored By: Representative Moore (UT)
In Committee
Summary
This bill would create a structured, four-year pathway that gives Medicare special, time-limited coverage for FDA-designated breakthrough medical devices. Coverage during that transition is tied to following FDA-approved labeling or to a Secretary review that the device's benefits outweigh its risks.
Show full summary
- Medicare beneficiaries: Seniors and other people on Parts A and B would have a defined four-year window of transitional coverage for devices the FDA designates as breakthrough. Coverage depends on using the device as labeled or on a Secretary risk-benefit finding.
- Device manufacturers: Manufacturers can seek a breakthrough designation starting 18 months after enactment and would get a decision within six months of application. A designation triggers the four-year transitional coverage period and faster coverage review timelines.
- CMS and providers: CMS must report annually on applications and designations and may review providers with unusual billing for these devices to protect program integrity. The Secretary must issue final national coverage decisions within set deadlines so decisions finish during the transition when requests meet timing rules.
*This bill would increase federal spending by $10 million per year from fiscal 2025 through 2030, about $60 million total, to fund CMS implementation and oversight.*
Bill Overview
Analyzed Economic Effects
4 provisions identified: 3 benefits, 0 costs, 1 mixed.
Faster Medicare decisions on new devices
If enacted, Medicare would need to finish a national coverage decision for a breakthrough device before its 4-year transition ends. This would apply when a request is filed at least 9 months before the end of the transition. In some cases, the filing would need to be 12 months ahead. This aims to give patients and providers clearer answers before temporary coverage runs out.
Temporary Medicare coverage for breakthrough devices
This bill would create a new path for some FDA-designated "breakthrough" devices to get Medicare coverage. Starting 18 months after enactment, makers could apply for a breakthrough label, and the Secretary would decide within 6 months. If designated, a 4-year transition period would start on the designation date. During that period, Medicare would cover the device only when used as the FDA label says for the priority-reviewed use. The Secretary could deny coverage if clinical data show the device’s risks outweigh its benefits.
Checks on unusual Medicare device billing
If enacted, the Secretary could review providers who bill unusually for a breakthrough device. Reviews would check if using the device was medically necessary and reasonable. This tool would target outliers and protect Medicare from improper payments.
Funds to run Medicare device program
This bill would give CMS $10 million each year from 2025 through 2030. The money would stay available until spent. CMS would use it to carry out the bill’s Medicare device coverage changes.
Sponsors & CoSponsors
Sponsor
Moore (UT)
UT • R
Cosponsors
DelBene
WA • D
Sponsored 9/15/2025
Yakym
IN • R
Sponsored 9/15/2025
Sewell
AL • D
Sponsored 9/15/2025
Bilirakis
FL • R
Sponsored 9/15/2025
Trahan
MA • D
Sponsored 9/15/2025
Tenney
NY • R
Sponsored 9/16/2025
Fischbach
MN • R
Sponsored 9/16/2025
Schneider
IL • D
Sponsored 9/17/2025
Correa
CA • D
Sponsored 9/19/2025
Carter (GA)
GA • R
Sponsored 10/31/2025
Auchincloss
MA • D
Sponsored 10/31/2025
Miller (WV)
WV • R
Sponsored 11/7/2025
Lieu
CA • D
Sponsored 11/7/2025
Owens
UT • R
Sponsored 11/18/2025
Bera
CA • D
Sponsored 11/18/2025
Weber (TX)
TX • R
Sponsored 12/2/2025
Soto
FL • D
Sponsored 12/2/2025
Kiggans (VA)
VA • R
Sponsored 12/9/2025
Pappas
NH • D
Sponsored 12/9/2025
Bean (FL)
FL • R
Sponsored 12/17/2025
Panetta
CA • D
Sponsored 1/6/2026
Bentz
OR • R
Sponsored 1/14/2026
Ross
NC • D
Sponsored 1/14/2026
Lawler
NY • R
Sponsored 2/3/2026
Strickland
WA • D
Sponsored 2/3/2026
Carey
OH • R
Sponsored 2/3/2026
Gottheimer
NJ • D
Sponsored 2/3/2026
Malliotakis
NY • R
Sponsored 2/3/2026
Pettersen
CO • D
Sponsored 2/3/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.govRelated Bills
HR842 — Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Would expand Medicare to cover multi-cancer early detection screening tests. It defines eligible tests as certain FDA-cleared or approved genomic blood tests or comparable biological-sample tests and directs the Secretary to use the national coverage determinations process to decide when they are covered.
HR1262 — Mikaela Naylon Give Kids a Chance Act
Speeds and strengthens pediatric cancer drug development. It expands which cancer products companies must study in children, reshapes organ transplant network governance and fees, and adds new FDA international and transparency steps. - Children with cancer and researchers: Requires pediatric studies that produce clinically meaningful data on dosing, safety, and early effectiveness and widens the kinds of drug combinations studied. It also sets aside $25 million for pediatric drug studies in each of fiscal years 2026, 2027, and 2028. - Transplant patients and transplant network members: Changes Organ Procurement and Transplantation Network governance and financing by allowing quarterly registration fees, requiring those fees fund OPTN operations, improving electronic health record integration, and calling for a GAO review within two years. - FDA partners and drug makers: Creates an Abraham Accords Office to boost regulatory coordination and technical assistance abroad, and forces more transparency during generic (ANDA) reviews about whether generics are qualitatively and quantitatively the same as listed drugs. It also raises the Medicare Improvement Fund amount from $1.4 billion to $2.6 billion. Increases federal outlays by roughly $1.3 billion, driven by a $1.2 billion boost to the Medicare Improvement Fund and $75 million for pediatric studies, adding to federal spending.
HR909 — Crime Victims Fund Stabilization Act of 2025
Would make the False Claims Act apply to deposits to the Crime Victims Fund through FY2029. It would also require an Inspector General audit that sets the audit's scope, timing, and recipients, and the measure is titled the Crime Victims Fund Stabilization Act of 2025. - Entities that make deposits to the Crime Victims Fund would be subject to the False Claims Act (31 U.S.C. 3729–3731) for deposits from enactment through FY2029. - An Inspector General audit would examine the Crime Victims Fund and the bill would set the audit's scope, timing, and who receives the report.
HR3514 — Improving Seniors’ Timely Access to Care Act of 2025
Standardize prior authorization in Medicare Advantage plans to make approvals faster and more transparent for beneficiaries and providers. The bill would require plans that use prior authorization to adopt a secure electronic PA program, publish plan-level PA data, and follow federal timeframes and enrollee protections.
HR1329 — Smithsonian American Women’s History Museum Act
Authorize the Smithsonian American Women's History Museum within the Reserve of the National Mall. It would remove an earlier site-designation limit, set a transfer and notification process for federal land, require exhibits to reflect diverse and authentic women's experiences with defined guidance, and mandate regular reports to Congress. - Smithsonian and the Board of Regents — Would be able to place the museum inside the National Mall Reserve and the bill removes a prior limiting phrase that constrained site designation. - Other federal agencies — Must receive notice before a site under their administrative jurisdiction is designated. The agency head must promptly notify specified House and Senate committees and then transfer administrative jurisdiction as soon as practicable. - Museum visitors and Congress — The Council must ensure exhibits and programs accurately represent varied cultures, histories, events, and values of women and seek guidance from a broad array of knowledgeable and respected sources with definitions for those terms. The Secretary must report to Congress 120 days after enactment and every two years on actions taken and planning.
HR452 — Miracle on Ice Congressional Gold Medal Act
This law awards Congressional Gold Medals to the 1980 U.S. Olympic Men's Ice Hockey Team as a formal recognition of their Lake Placid victory and its lasting effect on American morale and the sport of hockey. It directs the Treasury to strike the medals and sets rules for duplicates, display, and funding. - Team legacy and public recognition: The Act honors the 1980 team with a symbolic national award that reinforces their historical and cultural significance for fans, players, and communities connected to the game. - Museum displays and research access: One gold medal goes to the Lake Placid Olympic Center, one to the United States Hockey Hall of Fame Museum in Eveleth, Minnesota, and one to the United States Olympic & Paralympic Museum in Colorado Springs for display and research. - Mint operations and collectibles: The Secretary of the Treasury will strike the medals, may sell bronze duplicates at prices that cover costs, and classifies the medals as national and numismatic items. The U.S. Mint Public Enterprise Fund pays for production and receives proceeds from duplicate sales.
Take It Personal
Get Your Personalized Policy View
Create a free account to save research, track policy impacts, and unlock your personalized versions of these pages.
Already have an account? Sign in